Company News »

Osiris Therapeutics to Present at the 2014 Stem Cell Meeting on the Mesa

Business Wire
Share on StockTwits
Published on

Osiris Therapeutics, Inc. (NASDAQ:OSIR) , the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopedics and sports medicine markets, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the Stem Cell Meeting on the Mesa, on Tuesday, October 7, 2014 at 5:15 p.m. PST in La Jolla, CA.

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2014 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior executives and top decision makers in the regenerative medicine industry with the scientific community to advance cutting-edge research into cures. The Partnering Forum, held October 7 and 8 at the Estancia La Jolla Hotel, is the first and only partnering meeting of its kind dedicated solely to facilitating connections for the regenerative medicine and advanced therapies industry.

A replay of the webcast will be available following the conference through the Investors page of the Company’s website at www.Osiris.com.

In addition, Osiris will present a scientific poster describing the wound healing activities of cryopreserved vs non-cryopreserved placental membranes. This new study demonstrates that only the aseptic cryopreservation tissue processing method effectively protects the structural and cellular integrity of placental membranes in their native state. Preserving all tissue components including the three-dimensional tissue matrix architecture, growth factors, and tissue resident epithelial cells, fibroblasts, and mesenchymal stem cells is critical for tissue functionality. Cryopreserved placental membranes have significantly higher anti-inflammatory and anti-oxidant activities in comparison to non-cryopreserved membranes. Cryopreserved membranes also demonstrate enhanced cell recruitment and angiogenic potentials over non-cryopreserved membranes (p<0.05 for all tests). The poster titled “Tissue integrity is essential for the functionality of human placental membrane” will be presented at the Scientific Symposium on October 9th at the Stem Cell Meeting on the Mesa.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is the leading cellular regenerative medicine company, having developed the world’s first approved stem cell drug, remestemcel-L for graft versus host disease. Osiris’ products include Grafix(R) and for acute and chronic wounds, Cartiform(R), a viable cartilage mesh for cartilage repair and the latest addition to Osiris’ line of products, OvationOSTM, a viable bone matrix. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company’s technology and commercial interests.

Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company’s website, www.Osiris.com. (OSIR-G)

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine and advanced therapies. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 150 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our product and product candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for marketed Biosurgery products (including Grafix, OvationOS and Cartiform) and Biosurgery products under development; our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to address medical needs; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available products, to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research. Additional risks and uncertainties related to the sale of our ceMSC assets and the related transactions contemplated by the Purchase Agreement with Mesoblast include typical business transactional risks, the risk of changing relationships with customers, suppliers or employees, the risk associated with the disposition of our ceMSC assets and the increased relative dependence on and importance of our other business including our Biosurgery business, the risk that we may not be able to fully benefit from the transactions through milestone payments or royalties, payment risks, including the risk associated with receipt of equity as consideration, in lieu of cash, and the risk of dependence on others to achieve results upon which milestone or royalty payments to us are conditioned. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled “Risk Factors” in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

Share on StockTwits